Benitec Biopharma
BNTC
37 hedge funds and large institutions have $290M invested in Benitec Biopharma in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
23% more funds holding
Funds holding: 30 → 37 (+7)
21% more capital invested
Capital invested by funds: $240M → $290M (+$50M)
4.07% more ownership
Funds ownership: 81.82% → 85.89% (+4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$11.1M |
| 2 |
IAM
Infinitum Asset Management
Fort Lauderdale,
Florida
|
+$11.1M |
| 3 |
Janus Henderson Group
London,
|
+$3.66M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$3.02M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$951K |
| 2 |
6CM
683 Capital Management
New York
|
-$452K |
| 3 |
Morgan Stanley
New York
|
-$190K |
| 4 |
Citigroup
New York
|
-$76.3K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$22.9K |
BNTC Hedge Fund Activity: Q1 2025 in Review
37 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2025, worth a combined $290M — up 21% from $240M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BNTC positions and 3 closed out — a net gain of 7 holders — while 16 added to existing stakes and 6 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $11.1M. The largest seller was Franklin Resources, cutting an estimated $951K.
- 37 institutional investors held Benitec Biopharma (BNTC) as of Q1 2025, up from 30 in Q4 2024.
- Funds reported $290M of Benitec Biopharma stock for Q1 2025, up 21% quarter-over-quarter.
- 10 funds opened new Benitec Biopharma positions in Q1 2025 and 3 closed out, a net change of +7 holders.
- The largest Benitec Biopharma buyer in Q1 2025 was Suvretta Capital Management, an estimated $11.1M added.
- The largest Benitec Biopharma seller in Q1 2025 was Franklin Resources, an estimated $951K sold.
Based on aggregated 13F filings for Q1 2025.